Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein, for use in the treatment of diseases or disorders that can be alleviated by sGC activation or potentiation, selected from chronic liver diseases, Non-Alcoholic Steatohepatitis (NASH), cirrhosis and portal hypertension.
Abstract: Provided is a composition comprising suplatast tosilate or pharmaceutically acceptable derivatives thereof for use in a method of treating cough associated with interstitial lung disease, such as cough associated with pulmonary fibrosis.
Type:
Grant
Filed:
November 16, 2016
Date of Patent:
July 4, 2023
Assignee:
CONRIG PHARMA APS
Inventors:
John Bondo Hansen, Mikael S. Thomsen, Niels Skjærbæk
Abstract: A neuroprotective mixture includes Phosphocreatine (PCr), Magnesium Gluconate (MgG), and ß-hydroxybutyrate (BHB). The PCR, MgG, and BHB are combined in a 2:1:2 molar ratio of PCr:MgH:BHB. The neuroprotective mixture is a useful preventative and prophylactic supplement, which also can function to extend the post-stroke treatment window.
Type:
Grant
Filed:
November 16, 2020
Date of Patent:
July 4, 2023
Assignee:
TRICERAPRO HOLDING, LLC
Inventors:
Joseph L. Clark, Todd J. Crocco, Charles L. Rosen, Steven Cutright
Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
Type:
Grant
Filed:
July 2, 2021
Date of Patent:
July 4, 2023
Assignee:
CURTANA PHARMACEUTICALS, INC.
Inventors:
Graham Beaton, Fabio C. Tucci, Satheesh B. Ravula, Stanton F. McHardy, Francisco Xavier Ruiz, Ambrosio Lopez, Bismarck Campos, Hua-Yu Leo Wang
Abstract: The present invention provides a method of treating depression disease in a treatment resistant patient comprising administering to a mucosal membrane of a patient an effective amount of a pharmaceutically acceptable composition comprising an effective amount of ketamine or dextromethorphan, wherein the mucosal administration of the ketamine or dextromethorphan containing composition allows for the mucosal absorption of the composition eliminating the digestive tract of the patient for effecting a rapid acting antidepressant treatment of the treatment resistant patient. This method includes administering the composition to a patient's mucosal membrane of a respiratory tract, a genitourinary tract, an oral tract, or rectal tract of the patient. A pharmaceutically acceptable composition comprising ketamine or dextromethorphan and a vehicle is disclosed. A biomarker for identifying a depressive disease is set forth.
Type:
Grant
Filed:
February 4, 2022
Date of Patent:
June 27, 2023
Assignee:
West Virginia University
Inventors:
Scott Pollard, Patrick Marshalek, Rae Matsumoto
Abstract: Embodiments provided herein relate to methods and compositions for treating mesothelioma and/or a small cell lung cancer that express midkine.
Type:
Grant
Filed:
May 5, 2021
Date of Patent:
June 13, 2023
Assignee:
CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER
Inventors:
Jeffrey A. Whitsett, Yutaka Maeda, Takuya Fukazawa
Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type I), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp. infections, especially including Entamoeba histolytica.
Abstract: The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.
Type:
Grant
Filed:
May 28, 2019
Date of Patent:
June 6, 2023
Assignee:
HUA MEDICINE (SHANGHAI) LIMITED
Inventors:
Li Chen, Yongguo Li, Gaosen Wang, Huisheng Gao
Abstract: The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) a BCL-2 inhibitor, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
Abstract: Methods and compositions are provided for treating a patient having a bleeding disorder during or after a dental procedure to reduce bleeding or need for factor replacement therapy. Aqueous pharmaceutical compositions are provided comprising tranexamic acid, sodium carboxymethyl cellulose, Tween® 20, and menthol wherein the composition exhibits good long term stability, little to no discoloration over time, and reduced bitterness compared to a control solution of tranexamic acid and water.
Type:
Grant
Filed:
January 9, 2019
Date of Patent:
June 6, 2023
Assignee:
Hyloris Developments SA
Inventors:
Mary Beth G. Erstad, Thomas Gerner Jacobsen, Mohammad Alkhalili, L. Diane Bruce, Paul Hafey
Abstract: The invention discloses use of a conjugate of polyethylene glycol and a local anesthetic in non-anesthetic analgesia. A local anesthetic is prepared into a prodrug or a sustained release preparation, wherein a high molecular polymer such as polyethylene glycol in the prodrug is covalently bonded with a local anesthetic, and auxiliary materials with a sustained release effect in the sustained release preparation are non-covalently bonded to the local anesthetic. After administration, there is no anesthesia and analgesic effect before the release of the free local anesthetic. After the free local anesthetic is released, an analgesic effect is achieved.
Type:
Grant
Filed:
December 22, 2017
Date of Patent:
May 23, 2023
Assignee:
JENKEM TECHNOLOGY CO., LTD. (TIANJIN)
Inventors:
Zewang Feng, Jinliang Wang, Yanli Xiong, Juan Shi, Xuan Zhao
Abstract: This invention relate to solid oral dosage forms of tire HIV inhibitor Darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulation thereof.
Type:
Grant
Filed:
November 27, 2019
Date of Patent:
May 23, 2023
Assignee:
Janssen Sciences Ireland UC
Inventors:
Urbain Alfons C. Delaet, Philip Erna H. Heyns, Eugeen Maria Jozef Jans, Roel Jos M. Mertens, Geert Van Der Avoort
Abstract: An agent for elevating nitric oxide (NO) concentration comprising glutathione or a salt thereof as an active ingredient; an agent for elevating NO concentration comprising glutathione or a salt thereof as an active ingredient for preventing or ameliorating a vascular endothelial malfunction-related symptom, or dilating blood vessels or promoting blood flow by elevating NO concentration; and a method for elevating NO concentration by ingesting glutathione or a salt thereof.
Abstract: Liquid parenteral formulations are provided that include tigecycline and at least one or more pharmaceutically acceptable excipient or adjuvant, where the formulation is ready to use without additional steps for reconstitution at the time of administration.
Type:
Grant
Filed:
October 21, 2020
Date of Patent:
May 23, 2023
Assignee:
RK PHARMA INC.
Inventors:
Ravishanker Kovi, Jayaraman Kannappan, Sanjaysinh Fatesinh Thakor, Rahul Dixit
Abstract: The present application includes compositions for treating ectoparasite infestations, including killing ectoparasites and/or their ova, the compositions comprising one or more fatty acid esters and one or more linear polymeric siloxanes. Also included are kits comprising the compositions and methods of treating ectoparasite infestations, including methods of killing ectoparasites and/or their ova, using the compositions.
Type:
Grant
Filed:
May 12, 2022
Date of Patent:
May 23, 2023
Assignee:
Nuvo Pharmaceuticals (Ireland) Designated Activity Company
Inventors:
Bernard Joseph Chiasson, Robert Patrick Pearce, Chantal Paré
Abstract: Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
Type:
Grant
Filed:
January 26, 2021
Date of Patent:
May 16, 2023
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Inventors:
Albert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava
Abstract: A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in a polymeric film forming system. Advantageously, the film oral dosage form further includes a sweetener, a refreshing agent, an antioxidant, a pH stabilizer, a penetration enhancer, a mucoadhesive agent and a plasticizer. The loxapine film oral dosage form provides rapid onset of relief from acute agitation associated with schizophrenia or bipolar 1 disorder without presenting pulmonary health risks, thereby reducing risks to patients and others.
Abstract: Disclosed herein are new dosage regimens for deuterium-substituted benzoquinoline compounds, and methods for the treatment of abnormal muscular activity, movement disorders, and related conditions.